Neil James Clendeninn
Keine laufenden Positionen mehr
Profil
Neil James Clendeninn served as a Director at OncoGenex Technologies, Inc. from 2004 to 2008.
He also worked as a Director in the Clinical Oncology Department at Burroughs Wellcome.
He was an Independent Director at OncoGenex Pharmaceuticals, Inc. He served as the Chief Medical Officer & Senior Vice President at Heron Therapeutics, Inc. from 2015 to 2016.
He was the Vice President & Head of Clinical Affairs at Agouron Pharmaceuticals LLC from 1993 to 2001.
He was a Professor at The University of North Carolina at Charlotte.
Clendeninn holds a doctorate from New York University and an undergraduate degree from Wesleyan University.
Ehemalige bekannte Positionen von Neil James Clendeninn
| Unternehmen | Position | Ende |
|---|---|---|
| HERON THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 30.09.2016 |
OncoGenex Technologies, Inc.
 OncoGenex Technologies, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Technologies, Inc. develops drugs for cancer patients. Its products are being developed to block the production of specific proteins associated with the development of treatment resistance which will increase survival time and improve the quality of life for cancer patients. The company was founded in 2000 and is headquartered in Vancouver, Canada. | Direktor/Vorstandsmitglied | 22.08.2008 |
Agouron Pharmaceuticals LLC
 Agouron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Agouron Pharmaceuticals LLC develops and distributes therapeutic products. It provides therapeutic products which are used in the treatment of cardiovascular disease, central nervous system diseases and disorders, neurological disorders, inflammatory diseases, respiratory diseases, infectious diseases, immunological disorders, pharmaceutical preparations and other diseases. The company was founded in 1984 and is headquartered in San Diego, CA. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2001 |
National Cancer Institute
 National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Corporate Officer/Principal | - |
| The University of North Carolina at Charlotte | Corporate Officer/Principal | - |
Ausbildung von Neil James Clendeninn
| Wesleyan University | Undergraduate Degree |
| New York University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| HERON THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
OncoGenex Technologies, Inc.
OncoGenex Technologies, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Technologies, Inc. develops drugs for cancer patients. Its products are being developed to block the production of specific proteins associated with the development of treatment resistance which will increase survival time and improve the quality of life for cancer patients. The company was founded in 2000 and is headquartered in Vancouver, Canada. | Health Technology |
Agouron Pharmaceuticals LLC
Agouron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Agouron Pharmaceuticals LLC develops and distributes therapeutic products. It provides therapeutic products which are used in the treatment of cardiovascular disease, central nervous system diseases and disorders, neurological disorders, inflammatory diseases, respiratory diseases, infectious diseases, immunological disorders, pharmaceutical preparations and other diseases. The company was founded in 1984 and is headquartered in San Diego, CA. | Health Technology |
OncoGenex Pharmaceuticals, Inc.
 OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | Health Technology |
| Burroughs Wellcome | |
National Cancer Institute
National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Miscellaneous |
